Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) FCF Margin (2016 - 2025)

Vanda Pharmaceuticals' FCF Margin history spans 16 years, with the latest figure at 51.59% for Q4 2025.

  • On a quarterly basis, FCF Margin fell 4777.0% to 51.59% in Q4 2025 year-over-year; TTM through Dec 2025 was 51.1%, a 4293.0% decrease, with the full-year FY2025 number at 51.1%, down 4293.0% from a year prior.
  • FCF Margin hit 51.59% in Q4 2025 for Vanda Pharmaceuticals, up from 56.5% in the prior quarter.
  • Over the last five years, FCF Margin for VNDA hit a ceiling of 50.8% in Q1 2023 and a floor of 67.11% in Q1 2025.
  • Historically, FCF Margin has averaged 4.33% across 5 years, with a median of 1.39% in 2022.
  • Biggest five-year swings in FCF Margin: surged 4421bps in 2023 and later crashed -8304bps in 2025.
  • Tracing VNDA's FCF Margin over 5 years: stood at 38.92% in 2021, then crashed by -64bps to 14.19% in 2022, then tumbled by -162bps to 8.8% in 2023, then surged by 57bps to 3.82% in 2024, then plummeted by -1251bps to 51.59% in 2025.
  • Business Quant data shows FCF Margin for VNDA at 51.59% in Q4 2025, 56.5% in Q3 2025, and 29.57% in Q2 2025.